Company
Menarini
Menarini has 29 drugs tracked on RxWires: 5 post-market, 9 in Phase 3, 6 in Phase 2, 2 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Bilastine 20mg | Post-Market | Seasonal Allergic Rhinoconjunctivitis |
| Nebivolol 5 mg | Post-Market | Hypertension |
| Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg | Post-Market | Low Back Pain |
| Tramadol Hydrochloride/Dexketoprofen Trometamol | Post-Market | Acute Pain |
| metoprolol succinate | Post-Market | Hypertension |
| Elacestrant | Phase 3 | ER-positive Breast Cancer |
| Nebilet | Phase 3 | Primary Arterial Hypertension |
| Febuxostat | Phase 3 | Tumor Lysis Syndrome |
| Dexketoprofen/Tramadol-single dose | Phase 3 | Acute Pain |
| Bemiparin sodium | Phase 3 | Deep Vein Thrombosis |
| OM 40 | Phase 3 | Hypertension |
| Ibodutant 10 mg | Phase 3 | Irritable Bowel Syndrome With Diarrhea |
| Losartan and nebivolol | Phase 3 | Marfan Syndrome |
| Delafloxacin | Phase 3 | Surgical Site Infection |
| Nepadutant oral solution | Phase 2 | Infantile Colic |
| Ranolazine | Phase 2 | Persistent Atrial Fibrillation |
| Dexketoprofen Trometamol | Phase 2 | Pain |
| MEN16132 - 0.125 mg | Phase 2 | Osteoarthritis, Knee |
| Capecitabine | Phase 2 | Estrogen-receptor-positive Breast Cancer |
| Meropenem plus vaborbactam | Phase 2 | Gram Negative Infections |
| MEN1703 | Phase 1/2 | Acute Myeloid Leukemia |
| MEN1611 | Phase 1/2 | Metastatic Colorectal Cancer |
| Enantyum® oral solution | Phase 1 | Acute Pain |
| Levothyroxin | Phase 1 | Healthy |
| Ibuprofen 2% | Phase 1 | Healthy Male and Female Subjects |
| Tamsulosin (0.4 mg/j) | Phase 1 | Healthy Adult Males Volunteers |
| MEN1112 | Phase 1 | Recurrent Adult Acute Myeloid Leukemia |
| MEN1309 | Phase 1 | Metastatic Solid Tumors |
| Pigment Solution Program | Not Applicable | Melasma |
Latest
No recent events.
Follow Menarini on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.